Search PubMed⌕ Search

Biomedical subjects

J L Strominger

Publications and source records attributed to J L Strominger.

At least 361 records · Page 20Linked to original sources
PubMed1983

HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant.

The HLA-A2-specific mouse monoclonal antibody BB7.2 plus complement has been used to immunoselect variant clones of the lymphoblastoid cell line T5-1 (HLA-A1, -A2, -B8, and -B27). Members of one class of variant clones appear to express cell surface HLA-A2 molecules that display reduced reactivity with the selecting antibody, but normal or near normal reactivities with some other HLA-A2-specific monoclonal antibodies and human alloantisera. The HLA-A2 heavy chains derived from two of these variant clones were characterized by comparative double-label tryptic peptide mapping in conjunction with microsequence analysis. These heavy chains were found to carry distinct mutations in the same peptide in the molecule. We conclude that residues within this short segment of the polypeptide contribute to an HLA-A2-specific serological determinant.

Amino Acid Sequence↗
PubMed1983

Polymorphism and complexity of the human DC and murine I-A alpha chain genes.

A cDNA clone encoding the human B cell alloantigen DC alpha chain (pDCH1) has been used to analyse the structure of the human and murine major histocompatibility complexes by the DNA filter hybridization technique. The pDCH1 probe hybridizes to a single DNA sequence present on chromosome 17 in the mouse genome. A restriction enzyme polymorphism enables us to map this sequence to the I-A subregion. Extensive restriction enzyme polymorphism detected in HLA-DR homozygous typing cells is reminiscent of the DR/MT linkage disequilibrium groups, suggesting that the pDCH1 probe could be useful for haplotype typing in the human population. The HLA-DR region appears more complex than the I region since a second DC-like hybridizing sequence is detected in the human genome in these experiments.

Animals↗
PubMed1983

Structural polymorphism of the DC1 light chains from DR1-, DR2-, and DRw6-positive cell lines.

The heavy and light chain subunits of the DC1 antigen from several cell lines expressing different DR specificities were compared by two-dimensional (2-D) gel electrophoresis. The DC1 light chains from cell lines typed as DR1, DR2, or DRw6 differed in their isoelectric points. No difference in charge was observed for the DC1 heavy chain from the three cell lines. The DC1 light chains from different DRw6-positive cell lines were also found to be structurally polymorphic. The DRw6 cell lines examined did not all express the same DR-like light chains, indicating that the DRw6 specificity is biochemically complex, which is in agreement with the serologic studies of others.

Cell Line↗
PubMed1983

NH2-terminal sequence of the alpha and beta chains of human DC-1 antigen isolated from the JY cell line. Homology with murine I-A molecules.

The DC-1 antigen has been isolated from the JY cell line (DR4, w6). The amino terminal sequences of its alpha and beta chains are both reported and are homologous to the murine I-A antigens. The JY and previously reported LB DC-1 alpha chain sequences appear to be variants of the DC alpha chains reported by other authors. The JY DC-1 beta chain sequence appears to be identical with that deduced from a beta chain cDNA clone and thus identifies this clone. The JY and LB DC-1 beta-chains are clearly different since the latter has a blocked amino terminus.

Amino Acid Sequence↗
PubMed1983

A 55,000 Mr surface antigen on activated human T lymphocytes defined by a monoclonal antibody.

A T cell growth factor-dependent alloreactive human T cell line has been used to generate a monoclonal antibody B1.49.9 that reacts with an antigen present on most if not all mitogen or alloantigen activated T cells but not on resting T cells. The T lymphoblastoid cell line HUT-102 is also strongly reactive with B1.49.9 but all other T and non-T leukemia-lymphoma cell lines tested were negative. The B1.49.9 antigen is a glycoprotein of 55,000 Mr on mitogen or alloantigen activated T cells and 50,000 Mr on the cell line HUT-102. Pulse labeling experiments showed that a 40,000 Mr precursor (at approximately 0.7 h) which does not bind to ricin lectin precedes the appearance of the ricin-binding 55,000 Mr form. Comparisons of the monoclonal antibody anti-Tac, which recognizes the IL-2 receptor, to B1.49.9 suggest that B1.49.9 also recognizes a structure similar or identical to the IL-2 receptor.

Animals↗
PubMed1983

Analysis of human class II antigen alpha chain genes: a summary.

A cDNA clone corresponding to the HLA-DR alpha chain has been isolated following immunoprecipitation of polysomes with a monoclonal antibody against the denatured DR alpha chain. This cDNA clone has been used to isolate and solve the complete structure of the DR alpha chain gene and a cDNA clone corresponding to the DC alpha chain. The DR alpha and the DC alpha chains bear remarkable homology to each other and have one domain (alpha 2) which is a member of the immunoglobulin superfamily. The DC alpha chain gene has been demonstrated to be the homologue of the murine I-A alpha chain gene, and it has been localized on chromosome 6 using deletion mutants. A restriction enzyme polymorphism of the DC alpha chain gene has been detected in HLA-DR homozygous typing cells. This report is a summary of a presentation made at the HLA-DR meeting held in Marseille, France.

DNA↗
PubMed1983

HLA-A2 and HLA-B7 antigens are phosphorylated in vitro by rous sarcoma virus kinase (pp60v-src) at a tyrosine residue encoded in a highly conserved exon of the intracellular domain.

HLA-A2 and -B7 antigens are phosphorylated by Rous sarcoma kinase (pp60v-src) in vitro. The phosphate group is attached to the heavy chains as determined by NaDodSO4/polyacrylamide gel electrophoresis. The site of phosphorylation was localized to the COOH-terminal intracellular domain by its susceptibility to limited trypsin proteolysis. Furthermore, the 32P-labeled amino acid is a single tyrosine residue located in the COOH terminus of the heavy chain. The protein sequences of known class I human and murine intracellular domains contain a highly conserved sequence -K-G-G-X-Y- located NH2-terminally to the single tyrosine residue of this domain. The DNA sequences that encode class I antigen intracellular domains were compared by computer with a homology matrix program. Exon 6 which encodes the conserved tyrosine-containing protein sequence in both human and mouse is 75% homologous across species and 90-100% homologous within species. The significance of the high degree of conservation within exon 6 is discussed.

Amino Acid Sequence↗
PubMed1983

Genetic mapping of a human class II antigen beta-chain cDNA clone to the SB region of the HLA complex.

A class II antigen beta-chain cDNA clone was isolated from a human B-cell cDNA library by using as a probe the murine I-A beta gene. This cDNA clone, pHA beta, was shown to be distinct from the DC beta- and DR beta-related loci by DNA sequence analysis, thus suggesting that it might correspond to a third polymorphic human class II locus, SB, which encodes secondary B-cell antigens. Genetic mapping of this beta-chain cDNA clone to the SB region was performed by the blot hybridization procedure. We showed that (i) within panels of HLA-DR homozygous human B-cell lines and of unrelated individuals who have been typed for HLA antigens, differential mobility of DNA fragments segregated with distinct SB genotypes; (ii) gamma-ray-induced deletion mutants that have lost the expression of DR or DC/MT antigens but maintain SB expression preserved a pattern consistent with (a) their SB phenotype and (b) the genetic independence of the SB locus with respect to DR and DC/MT; and (iii) within an informative family, two siblings differing only for one allele at the SB locus (because of the occurrence of an internal recombination between DR and GLO) and otherwise HLA identical exhibited a restriction enzyme polymorphism linked to the SB locus. Therefore, all available data are compatible with identity between HA beta and SB beta.

Alleles↗
PubMed1983

Human lymphocyte function associated antigen-1 (LFA-1): identification of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity.

Human lymphocyte function-associated antigen (LFA)-1, a heterodimeric lymphocyte surface glycoprotein of 177,000 and 95,000 relative molecular weight has been implicated to function in the cytotoxic T lymphocyte (CTL) effector mechanism. Seven mouse hybridoma lines producing monoclonal antibodies (MAb) reactive with this structure were studied. Three unique and 3 partially over-lapping epitopes on human LFA-1 were defined by competitive cross inhibition binding assays using biosynthetically labeled anti-LFA-1 MAb. In contrast, of five rat antimouse LFA-1 MAb, all five recognized a common or shared epitope. An HLA-B7 specific human CTL line expressed 1.1 X 10(5) LFA-1 sites per cell with a direct saturation binding assay. Human CTL expressed two to four times more LFA-1 than peripheral blood lymphocytes or B and T lymphoblastoid cell lines. Titration of each of the anti-LFA-1 MAb in a 51chromium release cytolytic assay revealed quantitative differences in the ability of the different anti-LFA-1 MAb to block cytolysis indicating distinct functional and antigenic epitopes exist on the human LFA-1 molecule. Anti-LFA-1 MAb reversibly inhibited the CTL reaction by slowing the initial rate of cytolysis. These results suggest anti-LFA-1 MAb inhibit CTL function by specific blockade of a functionally relevant molecule.

Animals↗
PubMed1983

Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line.

HLA-A2 specific human cytotoxic T lymphocytes (CTL) cell lines have been developed using T cell growth factor and coculture of peripheral blood lymphocytes with selected allogeneic target cell lines. The CTL-8 line showed specificity for human leukocyte antigens (HLA)-A2 bearing target cells after 5 weeks in culture when tested against a panel of 14 lymphoblastoid cell lines in a 51Chromium (51Cr) release assay. Purified anti-human leukocyte antigens (HLA) monoclonal antibodies W6/32 and PA2.1 inhibited cytolysis by 85% and 60%, respectively. The CTL-8 line lysed non-HLA-A2 target cells in the presence of lectins concanavalin A (Con A) or phytohemagglutinin-P lectin (PHA-P) indicating the specificity of cytolysis was not due to nonspecific resistance of target cells to the CTL-lytic mechanism. The T5-1 HLA-A2 mutant cell series were tested as targets for the CTL-8 line. Cell clones 8.18.1, 8.21.1 and 8.6.1, which express altered HLA-A2 molecules as determined by their decreased reactivity with allospecific monoclonal antibodies, were lysed by the CTL-8 line as efficiently as the T5-1 wild type. These cell lines also acted as efficient cold target competitors for a normal HLA-A2 target cell. The 8.14.1 cell clone expressed a lower amount of HLA-A2 alloantigen and showed a corresponding decreased reactivity with CTL-8 in direct cytolytic and cold target competitive inhibition assays. In contrast, the M7 and DK1 HLA-A2 variant cell lines, which express normal HLA-A2 serological determinants, were inefficiently lysed by CTL-8 and did not act as competitive inhibitors of normal HLA-A2 target cells. These results support the concept that the alloantigenic determinant(s) recognized by T cells and antibodies occur at separate regions on the HLA-A2 molecule.

Animals↗
PubMed1983

Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant.

The HLA-A2 mutant cell line 8.6.1 was isolated previously from the lymphoblastoid B cell line T5-1 (HLA-A1, -A2, -B8, and -B27) by immunoselection with the mouse HLA-A2-specific monoclonal antibody BB7.2 and complement. The HLA-A2 molecules synthesized by 8.6.1 do not react with either the selecting antibody or with a second HLA-A2-specific monoclonal antibody, PA2.1. In this study, HLA-A2 heavy chains derived from 8.6.1 and those from the parent T5-1 cells have been analyzed by double-labeled tryptic peptide mapping by using reverse-phase HPLC, cation exchange chromatography, and microsequence analysis. We detect only a single difference between these molecules: 8.6.1 HLA-A2 differs from T5-1 HLA-A2 by the substitution of lysine for glutamic acid at position 161. This result is consistent with data derived from other immunoselected mutants, which implicate the second heavy chain domain (alpha 2) in the expression of the PA2.1 and BB7.2 epitopes, and suggests a crucial role for glutamic acid at position 161 in the formation of an HLA-A2-specific determinant.

Amino Acid Sequence↗
PubMed1983

Differentiation of human T lymphocytes. I. Acquisition of a novel human cell surface protein (p80) during normal intrathymic T cell maturation.

The thymus is thought to be the primary central lymphoid organ in which T cells mature. Although thymic cortical and medullary compartments are distinct histologically, few antigens have been described that are absolutely acquired during the presumed intrathymic maturation pathway from cortical to medullary thymocytes. In this paper, we describe the acquisition during human intrathymic T cell maturation of a novel protein (p80) defined by a monoclonal antibody (A1G3). Although the p80-A1G3 antigen is distributed throughout the body and is not T cell specific, our study demonstrates that expression of p80-A1G3 antigen in normal human thymus is associated with thymocyte functional maturity and location in the thymus medulla. Moreover, in contrast to other markers of mature human T cells, the p80-A1G3 cell surface protein is not expressed on T6+ cortical thymocytes, and, therefore, is absolutely acquired by medullary thymocytes during T cell maturation. Thus, the p80-A1G3 antigen and the A1G3 antibody provide a heretofore unavailable system for the study of molecular events that transpire during the maturation of thymocytes.

Adolescent↗
PubMed1983

Cytotoxic T cells directed against HLA-DR antigens and their surface proteins.

The authors review their recent research involving the generation of cytotoxic T lymphocytes (CTL) directed against HLA-DR antigens. A mouse anti-human xenogeneic system first suggested that HLA-DR antigens could be recognized by CTL. Human allogeneic CTL specific for HLA-DR6 were generated and found to be OKT4+. The fact that these CTL were OKT4+ while anti HLA-A,B CTL were OKT8+ suggested that these T cell surface antigens may be involved in MHC antigen recognition; ie, they may be part of the T cell receptor. These OKT4+, HLA-DR specific CTL were further used to generate monoclonal antibodies (1) which block cytolysis and define novel antigens involved in the CTL-target interaction and (2) which define an antigenic complex on alloantigen activated T cells.

Animals↗
PubMed1983

An unusually high-titer human anti-Epstein Barr virus (EBV) serum and its use in the study of EBV-specific proteins synthesized in vitro and in vivo.

Sera from a patient with a chronic Epstein Barr virus (EBV) infection contained unusually high anti-EBV antibody titers (1:2560 to 1:10,240 for EA(D) and 1:5,120 to 1:40,960 for VCA). One of these serum samples was shown by immunoprecipitation to recognize at least 11 EBV-specific proteins from virus producer cells labeled in vivo and 10 EBV-specific proteins from in vitro translations of producer cell mRNA. Six of the in vivo labeled proteins (135,000, 89,000, 50,000 to 55,000 doublet, 46,000, and 34,000 daltons) are "early" by their resistance to phosphonoacetic acid, and five (350,000, 220,000, 160,000, 140,000, and 85,000 daltons) are "late" membrane and capsid proteins. The EBV-specific proteins immunoprecipitated from in vitro translations had molecular masses of 150,000, 140,000, 115,000, 52,000, 50,000, 45,000, 34,000, 29,000, 17,000, and 15,000. Subcellular fractionation studies of cells labeled in vivo revealed that the 135,000-dalton protein and part of the 50,000 to 55,000 dalton protein doublet were found in both the nuclear and the cytoplasmic fractions, and thus are good candidates to be components of the EA(D) diffuse-type immunofluorescence observed with many EA-positive sera.

Adult↗
PubMed1983

The extracellular region of light chains from human and murine MHC class II antigens consists of two domains.

The experiments in this report, together with previous studies, demonstrate that the light chains of DR antigens are composed of four domains: two large extracellular domains (each with a disulfide loop), a short hydrophobic membrane-binding region, and a short hydrophilic carboxy-terminal domain. The amino-terminal extracellular domain is glycosylated and polymorphic and has no discernible sequence homology to immunoglobulin, whereas the relatively conserved carboxy-terminal extracellular domain bears striking homology to immunoglobulin. One chymotryptic and two tryptic cleavage sites lie in the second extracellular domain of the light chain of all native DR antigens. These three sites are found in loops at the same end of an immunoglobulin-like domain. The light chain of DC1 antigen lacks one of the tryptic cleavage sites; the DR heavy chain, the class I heavy chain, and beta 2 microglobulin lack all three proteolytic sites. Proteolysis of murine la antigens with chymotrypsin and trypsin generates similar fragments (I-E-like DR, I-A-like DC1) suggesting these cleavage sites are a general feature of class II antigen light chains.

Amino Acid Sequence↗
PubMed1983

Characterization of a novel differentiation antigen complex recognize by a monoclonal antibody (A-1A5): unique activation-specific molecular forms on stimulated T cells.

By using a single monoclonal antibody, a novel glycoprotein complex composed of at least three distinct bands was defined on the surface of mitogen- or alloantigen-stimulated T cells. These bands (210,000, 165,000, and 130,000 Mr) were not disulfide linked and could be radio-labeled with 125I or 35S-methionine and readily detected by immunoprecipitation with the monoclonal antibody A-1A5. Only approximately 20% of normal T cells (E rosette positive) and approximately 47% non-T cells (E rosette negative) were reactive with A-1A5. However, upon activation of T cells, the amount of A-1A5 binding per cell and the percentage of positive cells significantly increased. This increase was most pronounced in the activated cell subpopulations currently undergoing cell division (S, G2, and M phases), which became 79% A-1A5 positive (after PHA stimulation) and 99% A-1A5 positive (in long-term culture with alloantigen and IL2). Resting lymphocytes contained only the 130,000 Mr band reactive with A-1A5. The two other bands (210,000 and 165,000 Mr) were markers for T cell activation and only appeared several days after T cell stimulation and became especially prominent after the addition of exogenous IL 2. All T lymphoblastoid cell lines tested expressed at least the lower bands (130,000 Mr), and the T cell line HSB also expressed one of the activation-related larger proteins (165,000 Mr). B lymphoblastoid cell lines expressed only a very weak lower band (130,000 Mr), and the cell line U-937 (in the monocyte-macrophage lineage) expressed only a single band (145,000 Mr) not aligned with any of the bands found on lymphoid cells. The estimated number of A-1A5 binding sites per cell was much higher on U-937 (11 X 10(5)), and generally higher on other cell lines of myeloid lineage (1 to 4 X 10(5)) than on lymphoid cell lines (0.2 to 1.3 X 10(5)).

Animals↗
PubMed1983

Analysis of the oligosaccharides on the HLA-DR and DC1 B cell antigens.

The types of N-linked oligosaccharides on the HLA-DR and DC1 antigens were determined by their sensitivity to endoglycosidase H or endoglycosidase D. The DR and DC1 heavy chains each have two carbohydrate moieties, one high-mannose and one complex-type glycan. The DR and DC1 light chains have one complex-type oligosaccharide. During the biosynthesis of the DR antigens, the oligosaccharides on both subunits are initially high-mannose-type glycans, as has been found for other membrane glycoproteins. The light chain oligosaccharide and one of the two heavy chain carbohydrates are later processed to complex-type glycans. Inhibition of N-linked glycosylation with tunicamycin does not inhibit chain association of the DR and DC1 subunits, transport to the cell surface, or expression of the alloantigenic determinants.

Antigens, Surface↗